Oncology

Featured

Videos

Innovation and the Future Development of Cell Therapies for Patients With B-Cell Lymphomas

08/05/2024

At the 2024 Pan Pacific Lymphoma Conference, Nirav Shah, MD, discusses innovation and the future development of cell therapies for patients with various types of B-cell malignancies.

At the 2024 Pan Pacific Lymphoma...

08/05/2024

Oncology

Videos

Exploring Triplet Therapy for Patients With AML Ineligible for Intensive Induction Chemotherapy

08/05/2024

Curtis Lachowiez, MD, participated in a debate at the 2024 Great Debates and Updates meeting in which he argued in favor of triplet therapy for patients with acute myeloid leukemia who are unable to receive intensive induction chemotherapy.

Curtis Lachowiez, MD,...

08/05/2024

Oncology

Videos

Should Additional BCMA Therapy be Utilized After Prior BCMA Treatment for Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued in favor of using additional BCMA-directed therapy after prior BCMA-directed therapy for patients with multiple myeloma.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Should Stem Cell Transplantation be Suggested for Older Patients With Multiple Myeloma?

07/31/2024

Ajai Chari, MD, participated in a debate at the 2024 Great Debates & Updates meeting in which he argued against the use of stem cell transplantation for patients with multiple myeloma over the age of 65.

Ajai Chari, MD, participated in...

07/31/2024

Oncology

Videos

Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL

07/29/2024

Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...

Elizabeth Brem, MD, shares...

07/29/2024

Oncology

Videos

CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL

07/29/2024

At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.

At the 2024 Great Debates &...

07/29/2024

Oncology

Videos

Benefits of Utilizing CAR-T in Later Lines of Therapy for Patients With Multiple Myeloma

07/28/2024

At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Should Autologous Stem Cell Transplantation be Considered for Older Patients With Multiple Myeloma?

07/28/2024

At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Should Minimal Residual Disease Guide Therapy for Patients With Multiple Myeloma?

07/28/2024

At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.

At the 2024 Great Debates &...

07/28/2024

Oncology

Videos

Examining Risk Stratification and Novel Treatment Options for Patients With Low and Intermediate-Risk MDS

07/28/2024

Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.

Pinkal Desai, MD, discusses risk...

07/28/2024

Oncology

Videos

Assessing the Impact of FDA Approval of Pirtobrutinib in the R/R Chronic Lymphocytic Leukemia Treatment Landscape

07/28/2024

Inhye Ahn, MD, shares insight into the real-world practice impact of the FDA approval of non-covalent Bruton tyrosine kinase inhibitor pirtobrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have...

Inhye Ahn, MD, shares insight...

07/28/2024

Lymphoma, Leukemia & Myeloma Network

From Lymphoma, Leukemia & Myeloma Network

https://www.hmpgloballearningnetwork.com/site/onc-app

Insights From the ESMO Congress

Conference Coverage

Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma

11/22/2023

Stephanie Holland

Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.

Biomarker analyses from patients...

11/22/2023

Oncology

Quiz

Tisotumab Vedotin for Cervical Cancer

11/21/2023

Oncology

Conference Coverage

Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma

11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...

Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.

Juergen C. Becker, MD, PhD,...

11/20/2023

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Featuring Sara Lonardi, MD

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

Kohei Shitara, MD, PhD, National Cancer Center Hospital East

Videos

Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer

11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study,...

11/14/2023

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases

08/02/2024

Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.

Rene Adam, MD, PhD, discusses...

08/02/2024

Oncology

Videos

Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Eligible Patients With Newly Diagnosed MM

07/27/2024

Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.

Paula Rodríguez-Otero, MD,...

07/27/2024

Oncology

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/22/2024

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses...

07/22/2024

Oncology

Conference Coverage

Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer

07/19/2024

David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

David Spigel, MD, discusses the...

07/19/2024

Oncology

Conference Coverage

Regorafenib Plus Pembrolizumab Among Patients With Advanced Hepatocellular Carcinoma Previously Exposed to Immunotherapy

07/18/2024

Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...

Anthony El-Khoueiry, MD,...

07/18/2024

Oncology

News

Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases

07/18/2024

Allison Casey ;

According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.

According to the phase 3...

07/18/2024

IO Learning

Conference Coverage

Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM

07/02/2024

At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.

At the 2024 ASCO Annual Meeting,...

07/02/2024

Oncology

Conference Coverage

Nivolumab Plus Ipilimumab As Potential New Frontline Option for Patients With Unresectable Hepatocellular Carcinoma

07/02/2024

Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.

Peter Galle, MD, PhD, discussed...

07/02/2024

Oncology

Conference Coverage

Neoadjuvant Dostarlimab for Patients With Locally Advanced Mismatch Repair Deficient Rectal Cancer

07/01/2024

Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.

Andrea Cercek, MD, discussed...

07/01/2024

Oncology

Conference Coverage

Gemcitabine and Nab-Paclitaxel vs 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Metastatic Pancreatic Ductal Adenocarcinoma

06/28/2024

Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.

Efrat Dotan, MD, discussed...

06/28/2024

Oncology

Biological Pathway Reviews

Live Meetings

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology